Home / Browse Journals & Books / Annals of Lung Cancer / Archive / Volume 1, Issue 1
Research Article Pages 35-38
Abstract: Nivolumab (Nivo) is a programmed death receptor-1 immune check point antibody widely used in cancer.
| | |
Research Article Pages 30-34
Abstract: The efficacy and safety of the Immune Check Point Inhibitors (ICPI) have been well documented. Their costs and values have received lesser attention.
Case Study Pages 25-29
Abstract: Pseudoprogression is a challenging obstacle in the interpretation of therapeutic response to radiation and chemotherapies for metastatic brain lesions. Combination of stereotactic radio surgery post-treatment effects and anti-PD-1 antibody therapy may cause benign edematous enhancements in treated brain metastases which mimic tumor progression.
REVIEW ARTICLE Pages 15-24
Abstract: Small Cell Lung Cancer (SCLC) represents between 13-15% of all lung cancers; however is the fifth leading cause of cancer death worldwide. SCLC prognosis remains poor despite improvements in diagnosis and treatment over the last 30 years.
Research Article Pages 10-14
Abstract: To evaluate a possible influence of confounding in risk estimation for lung cancer in relation to silica dust exposure, we re-analyze a recently published exposure-response relationship using a sub-cohort of Chinese tungsten miners which has no relevant occupational confounders.
Research Article Pages 1-9
Abstract: Stereotactic Body Radiation Therapy (SBRT) has rapidly emerged as a curative procedure for early stage non-small cell lung cancer (NSCLC). The ablative hypo-fractionated radiation doses used with SBRT requires very small tumor margins, making tumor motion management very important to reduce the risk of long term morbidity.
Track your Manuscript Status